Loading patent…
AssigneesOlga Matveeva, Anna Senina
InventorsOlga Matveeva, Anna Senina, Vyacheslav Slav Mikhailovich Senin
Estimating the term…
The invention relates to the field of immunology and medicine, more specifically, oncology, and can be useful for the treatment of patients with carcinomas and sarcomas. A pharmaceutical composition is provided which contains biologically active oncolytic Sendai virus strain Moscow PTA-13024, and a method of treating patients with said malignancies is developed including administration of the said composition to a patient's body. The strain Sendai-Moscow deposited into ATCC as frozen allantoic fluid (deposit PTA-13024) and as lyophilized form (deposit PTA-121432) is characterized by high oncolytic activity and safety for humans. The exploitation of the invention allows an increase in efficacy of treatment due to direct elimination of malignant cells via virus action and induction of anti-tumor immunity by viruses.
A method of treating cancer that includes administering to a human or animal patient in need thereof a composition containing an isolated, native, biologically active virus Sendai strain deposited at ATCC under Accession Number PTA-13024 or under Accession Number PTA-121432 and a pharmaceutically acceptable carrier.
A pharmaceutical composition for therapeutic use containing isolated, native, biologically active virus Sendai strain deposited at ATCC under Accession Number PTA-13024 or under Accession Number PTA-121432 and pharmaceutically acceptable carrier.
A pharmaceutical composition for therapeutic use containing isolated, genetically engineered, biologically active virus Sendai strain prepared on the basis of the viral material deposited at ATCC under Accession Number PTA-13024 or under Accession Number PTA-121432 and pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.